Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
Activity Details
|
|
|
|
248 !
|
Mon, 7/30/2018,
2:00 PM -
3:50 PM
|
CC-West 119
|
|
Statistical Issues Specific the Therapeutic Areas- 2 — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Jie Li Jie Li
|
|
2:05 PM
|
A Meta-Analysis to Indirectly Compare Experimental Drugs Across Multiple Indications Using a Bayesian Hierarchical Model
Ji Lin, Eli Lilly; Jingyi Liu, Eli Lilly; Zachary Thomas, Eli Lilly; Yumin Zhao, Eli Lilly & Co.; Mythili Koneru, Eli Lilly
|
|
2:20 PM
|
Sample Size Determination Under Non-Proportional Hazards
Zhaowei Hua, Takeda Pharmaceuticals International Co.; Miao Yang, Oregon State University; Saran Vardhanabhuti, Takeda Pharmaceuticals
|
|
2:35 PM
|
Are Tumor Size Changes Predictive of Survival for Immunotherapy Trials?
Meihua Wang, Merck & Co.; Thomas Jemielita, Merck & Co.; Cong Chen, Merck & Co.; Chen Hu, Johns Hopkins University
|
|
2:50 PM
|
Does Phase 2 PFS or ORR Predict Phase 3 OS?
Russell Reeve, Quintiles
|
|
3:05 PM
|
Innovative Approaches to Deal with Delayed Treatment Effect, Cure Fraction and Treatment Switching in Time-To-Event Data in Cancer Immuno-Therapies
Carl Di Casoli, Halozyme Therapeutics; Alessandro Previtali, Celgene; Jonathan Jaeger, Celgene; Marie-Laure Casaebaig, Celgene
|
|
3:20 PM
|
A Simulation-Based Comparison Study About Different Methods Adjusting for the Bias of Treatment Non-Adherence
Jia Jia, AbbVie; Ying Zhang, Penn State College of Medicine; Jane Qian, Abbvie
|
|
3:35 PM
|
Predictive Probability on Interim Analysis of Time-To-Event Endpoints with Delayed Treatment Effects
Matt Rosales, Astellas; Kentaro Takeda, Astellas Pharma Global Development, Inc.
|
|
